Biogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled.
Biogen will replace its CEO and largely abandon marketing of itsAduhelm less than a year after the medication's launch triggered a backlash from experts, doctors and insurers.
For now, Biogen announced it is “substantially eliminating” spending on Aduhelm as part of a $1 billion dollar cost-saving plan designed to refocus the company's flagging pharmaceutical business. Aduhelm was the first new Alzheimer’s drug introduction in nearly two decades. Initially priced at $56,000 a year, it was expected to quickly become a blockbuster drug that would generate billions for Biogen.
Last month the federal government's Medicare health plan imposed strict coverage limitations on who can get the drug, which brought in $2.8 million in sales in the first quarter, which just ended. The vast majority of U.S. Alzheimer's patients are old enough to qualify for Medicare, which covers more than 60 million people, including those 65 and older, and disabled people under 65.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
The Forbes CIO Next List: 2022Recognizing 50 top tech leaders who are redefining the CIO role and driving game-changing innovation:
Consulte Mais informação »
Heat Check: Brandon Inniss Moves into the Top Spot on Ohio State's 2023 Recruiting Board Following Spring VisitsHeat Check: Brandon Inniss slots into the No. 1 spot while two new names make an appearance on the board of Ohio State’s top targets for the recruiting class of 2023.
Consulte Mais informação »
Concert at RFK heard across D.C. and into suburbs because of weatherEvents D.C., the city’s official convention and sports authority, said it is a 'top priority' to make changes that mitigate this kind of noise from future events.
Consulte Mais informação »
FDA Rejects Two Proposed Cancer Drugs Developed in ChinaThe Food and Drug Administration rejected two proposed cancer drugs that were developed in China, underscoring a tougher U.S. regulatory stance toward such drugs
Consulte Mais informação »
Arizona’s ‘Right to Try 2.0’In 2018, former President Donald Trump signed into law a bill that gave terminally ill patients the right to try experimental drugs not yet approved by the U.S. Food and Drug Administration.
Consulte Mais informação »